Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in EAEU has been experiencing significant growth in recent years, driven by a variety of factors such as increasing cancer prevalence, rising healthcare expenditure, and advancements in drug research and development.
Customer preferences: Patients in the EAEU region have shown a growing preference for targeted therapies and immunotherapies over traditional chemotherapy. These therapies have been found to be more effective and have fewer side effects, leading to increased demand for these drugs in the market.
Trends in the market: Russia is the largest market for oncology drugs in the EAEU region, accounting for the majority of sales. The market is dominated by multinational pharmaceutical companies, with a few local players also present. The market has seen a shift towards more innovative and targeted therapies, with a growing focus on precision medicine. Biosimilars are also gaining popularity in the market, as they offer a more affordable alternative to expensive biologic drugs.
Local special circumstances: The EAEU region has a high burden of cancer, with lung, breast, and colorectal cancers being the most prevalent types. The region also has a rapidly aging population, which is expected to drive up cancer incidence rates in the coming years. Additionally, there is a lack of oncologists and cancer treatment centers in some parts of the region, leading to disparities in access to care.
Underlying macroeconomic factors: The EAEU region has been experiencing economic growth in recent years, which has led to an increase in healthcare spending. Governments in the region are also implementing policies to improve access to cancer care, such as expanding insurance coverage and investing in healthcare infrastructure. However, the region still faces challenges such as corruption and political instability, which can impact the healthcare sector.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
